GSK makes FDA bid for first-line Arzerra use; Irish pharma jobs shrink by up to 20%; Russian pharma eyes Brazilian biosims market;

@FiercePharma:  ICYMI, most popular special report this weekend: Top 15 Drug Launch Superstars | Follow @FiercePharma

@EricPFierce: Novartis' Sandoz is the 2nd largest generics maker in the world. It targets biosimilars to stay there. More | Follow @EricPFierce

@CarlyHFierce: We now present: Top 10 generics makers by 2012 revenue. Special report | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) and Genmab asked the FDA to approve first-line use of their chronic lymphocytic leukemia drug Arzerra. Report

> The Irish pharma industry has lost up to 20% of its jobs over the past 3 to 5 years as patent-cliff losses hit local Big Pharma operations. Report

> Russia's Biocad is set to open a $40 million plant in Brazil to make three biosimilar drugs for sale in that market. Report

> Iroko Pharmaceuticals won the FDA nod for its pain drug Zorvolex (diclofenac), a non-steroidal anti-inflammatory, at dosages 20% lower than other available versions. Report

> Specialty drugmaker Meda closed its $135 million buyout of Acton Pharmaceuticals and its product Aerospan. Report

> Three dozen lawsuits alleging that Pfizer's ($PFE) Lipitor is unsafe were transferred to federal court; in responding to the suit, Pfizer said Lipitor's risks are outweighed by its benefits. Report

> Smaller Indian drugmakers such as Intas Pharmaceuticals, Macleods Pharma and Hetero Labs are tapping the U.S. market. Report

Medical Device News

@FierceMedDev: Cheney worried defibrillator was vulnerable to hacking from terrorists. Item | Follow @FierceMedDev

@MarkHFierce: Kona Medical, a 2013 Fierce 15 winner, drew in $10M in new funding to hit China with its renal denervation device. Release | Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: AstraZeneca teams with Taris to research bladder cancer delivery device. Story from FierceDrugDelivery | Follow @MichaelGFierce

> DoD ponies up $15M to develop Terumo's blood-cleaning tech. News

> Bard recalls vascular stent due to deployment malfunction risks. Story

> Medtronic launches clot-removal tech in U.S. Article

Biotech News

@FierceBiotech: ICYMI last week: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceBiotech

@JohnCFierce: Latest biotech IPO tally: 39 done, 15 in the queue--report updated with stock performance as of last Thursday. Feature | Follow @JohnCFierce

@DamianFierce: Quintiles is shuttering an early-phase Indian facility as regulatory hurdles make times tough. FierceCRO article | Follow @DamianFierce

@EmilyMFierce: FierceBiotech is looking for an associate editor. Details here | Follow @EmilyMFierce

> Iroko gets a thumbs-up from FDA on lower-dose NSAID. Item

> Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib. Article

> TetraLogic joins IPO rush with $103.5M offering to fuel cancer drug R&D. News

> Lilly's Lechleiter isn't budging from stand-alone $5B R&D strategy--yet. Story

> Actelion wins crucial FDA approval for next-gen lung disease drug Opsumit. News

CRO News

> WuXi is first in China with CLIA-OK genomics lab. Item

> Novella teams with Scioderm for 'breakthrough' drug. More

> DrugDev picks up CFS Clinical for trial software. Story

> Aenova snags Haupt to boost CMO presence. News

> Clinlogix buys German CRO with eye on Euro demand. Article

Biotech IT News

> Pfizer and Roche back protein shape change monitoring startup. Story

> Deloitte unveils another EHR-driven software tool. News

> Statisticians fret over misuse of data-crunching software. More

> Veeva stock soars following successful IPO. Article

> Roche to shutter 454, 6 years after buying NGS business. Story

And Finally... Brazilian animal-rights activists released 178 beagles used in pharma research as part of a raucous protest at the Instituto Royal lab in Sao Roque. Report

Suggested Articles

Long-time trend watcher and marketer Rohit Bhargava challenged pharma marketers to adopt new habits to become non-obvious thinkers.

Samsung Biologics opened the doors to its first-ever US CDO R&D Center in San Francisco.

When the COVID-19 pandemic began, early fears of shortages of pharmaceutical supplies and drugs were quickly abated by a responsive supply chain.